JPRN-jRCTs071180016已完成2 期
Analysis on response to darbepoetin alfa in patients with low risk myelodysplastic syndromes. - W-JHS MDS01
Mitani Kinuko0 个研究点目标入组 85 人开始时间: 2019年2月13日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 85
研究概览
简要总结
High-frequency (10% or more) gene mutations were found in SF3B1 (24 cases, 30.4%), TET2 (20 cases, 25.3%), SRSF2 (10 cases, 12.7%), ASXL1 (9 cases, 11.4%), and DNMT3A (8 cases, 10.1%). Overall response rate was 70.9%. Univariate logistic regression analysis did not show any significant association between these mutations and therapeutic efficacy of DA. The same results were obtained when the analysis was limited to red blood cell transfusion-dependent patients (n=15). To adjust against baseline erythropoiet
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 16age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1) Patients with definite diagnosis of MDS in diagnostic criteria of refractory anemia (myelodysplastic syndrome) (MHLW, Research and study group on idiopathic hematopoietic disorder, revised in 2010 fiscal year).
- •2) Patients having anemia associated with MDS, and is aged 16 years or older.
- •3) Patients categorized in Low or Int-1 risk in IPSS risk categories.
- •4) Patients who can visit participating institutions in prescribed schedule.
- •5) Patients providing the written informed consent (in the case of minor subject, taking from both the subject and legal representative).
排除标准
- •1) Patients at risk of thromboembolism with present or past medical history of myocardial infarction, pulmonary infarction and cerebral infarction or similar disorders..
- •2) Patients with uncontrollable hypertension.
- •3) Patients with medical history of drug hypersensitivity to darbepoetin alfa or other erythropoietin formulation.
- •4) Patients with severe (need for hospital care, or judgement by investigators) or uncontrollable complication.
- •5) Patients inappropriate for study participation due to complication of mental disease or psychiatric symptom.
- •6) Patients with cognitive disorder.
- •7) Patients judged by investigators to be inappropriate for study participation.
研究者
相似试验
招募中
不适用
BAFF-var as a Biomarker of Response to B-depletive Treatment in Systemic Lupus Erythematosus and Rheumatoid ArthritisBLyS PolymorphismRheumatoid ArthritisSystemic Lupus ErythematosusNCT05659407University of Cagliari60
已完成
不适用
Genetic Factors Affecting the Severity of Beta ThalassemiaBeta ThalassemiaNCT00159042Deborah Rund50
撤回
2 期
"Dabrafenib and Trametinib in Circulating Free DNA BRAFV600 Mutated Metastatic Melanoma Patients: a Prospective Phase II, Open Label, Multicentre Study - (Bioliquid TAILOR Study - BIOTAILOR)"MelanomaNCT05299580Fondazione Melanoma Onlus
已完成
不适用
Effect of Genetic Polymorphisms on Response to Beta Blocker Therapy in Egyptian PatientsHypertensionAcute Coronary SyndromeNCT04900545Mohamed Saleh Fayed80
Unknown
不适用
The Influence of Gene Polymorphism on Clinical Outcomes in Patients Undergoing PCIAntiplatelet TherapyCYP2C19 PolymorphismNCT03758248Beijing Anzhen Hospital12,000